T1	intervention 60 69	vitamin D
T2	eligibility 530 568	Newly diagnosed breast cancer patients
T3	control 631 638	placebo
T4	duration 648 655	6 weeks
T5	No-of-participants 863 865	83
T6	No-of-participants 887 889	80
T7	intervention-participants 911 913	43
T8	control-participants 936 938	37
T9	outcome 1104 1140	percent changes of either Ki67 index
T10	outcome 1171 1174	CC3
T11	outcome 1208 1249	Serum 25-hydroxyvitamin D (25-OHD) levels
T12	outcome 1330 1345	Adverse effects
